analysis. A group of patients with falciparum malaria (n = 51) selected for comparisons did not differ with regard to demographic data. The diagnosis was based on the positive results of a microscopic examination of the Giemsa -stained thick and thin peripheral blood smears, rapid diagnostic test (RDT), and polymerase -chain reaction assay. The microscopic examination of stained peripheral blood smears was used as the primary diagnostic tool because it remains the gold standard for the diagnosis of malaria. However, its accuracy and effectiveness may be unsatisfactory for low parasite densities or in the case of low -quality blood smear. The RDT (OptiMAL -IT, Bio -Rad, Marnes -la -Coquette, France), which can distinguish between falciparum and nonfalciparum infection, was used as an alternative when microscopy was not available in urgent cases in order to obtain results in patients suspected of acute malaria. The test is highly specific and is capable of detecting as few as 50 to 100 parasites per μl of blood. To be a useful diagnostic tool, the RDT must achieve sensitivity greater than 95%. Patients with positive or negative RDT results were then subject to the microscopic examination to confirm the result. A nested polymerase-chain reaction assay targeting the Plasmodium spp. 18S rRNA gene was used to increase the sensitivity of malaria diagnosis, especially in the case of low parasite count and mixed infections when there was a difficulty in identifying the species.
Severe (complicated) malaria was defined according to the World Health Organization criteria.
6 Latency was calculated as the number of days between arrival to Poland and malaria diagnosis. Long -term travel was defined as travel exceeding 24 weeks of stay in an endemic region. A retrospective analysis of medical records was performed.
Introduction Plasmodium vivax (P. vivax) is responsible for tertian malaria, a disease prevalent in many countries within tropical, subtropical, and moderate climate zones. It is also the second most common species responsible for imported Plasmodium infections in Europe. 1,2 In Asia, P. vivax is diagnosed in more than half of all malaria patients, while in Central and South America it is responsible for 71% to 81% of cases. 1, 3, 4 Late onset of symptoms, related to the incubation period of several weeks or months, and clinical relapses contribute to challenges associated with imported vivax malaria. Relapses are caused by hypnozoites, the unique stage of P. vivax and P. ovale species, and can be prevented by using primaquine. Unlike falciparum malaria, tertian malaria has traditionally been considered a benign form of infection. However, severe manifestations, including fatalities, have been increasingly reported in P. vivax infections, especially during the last decade. 5 The number of malaria cases in Poland is low and usually does not exceed 40 per year. All of them are imported because Poland was declared free from autochthonous transmission in 1963.
The aim of this study was to assess clinical features of imported P. vivax malaria in a group of patients diagnosed and treated at the University Centre for Maritime and Tropical Medicine in Gdynia, Poland, between the years 2003 and 2015, with a focus on the incidence and manifestations of severe cases.
Patients and methods A total of 85 cases of malaria were diagnosed at the University Centre for Maritime and Tropical Medicine during the study period, including 25 cases (29.4%) of primary vivax malaria, which were included in a detailed Mild anemia was diagnosed in 8 patients (32%), and thrombocytopenia-in 16 cases (64%). The median platelet count in the vivax malaria group was significantly higher than in the falciparum malaria group (86 × 10 9 /l [range, 30-137] and 54 × 10 9 /l [range, 28-129]; P = 0.04), while the mean parasite count was lower (0.17% [range, 0.01-0.1] and 1.7% [range, 0.01-7.4], respectively; P = 0.002). In 4 cases, mixed infection was detected.
An abdominal ultrasound examination showed spleen enlargement in 16 patients and hepatomegaly in 15 patients, while 14 patients were diagnosed with hepatosplenomegaly.
Abnormal radiographic findings included bronchiolitis obliterans organizing pneumonia (BOOP) and consolidations in 1 patient and hydrothorax in another patient. Those 2 patients (8%) fulfilled the criteria for severe malaria. The first patient was a 62 -year -old man with hypertension and diabetes who returned from Venezuela and developed pulmonary distress (BOOP) after the introduction of antimalarial treatment. The second patient was an 18 -year -old woman with a history of recent school trip to India, circulatory collapse, thrombocytopenia, and suspected Klebsiella pneumoniae ESBL (+) urosepsis. Both patients suffered from Plasmodium monoinfection.
Discussion All Plasmodium infections in Poland are treated in the hospital setting, and almost one -third of patients are admitted to the University Centre for Maritime and Tropical Medicine. In the years 2003-2015, 29.4% of patients at the Centre were diagnosed with P. vivax. This rate seems to be higher than that reported in other European studies (12.9%-25.4%) and may be explained by travel patterns of Polish citizens.
2,11,12 In our patients, travel to South America or Asia was indicative of the highest relative risk of P. vivax diagnosis. On the other hand, the relative low popularity of VFR travel ("visiting friends and relatives") to Africa could also contribute to this finding.
For years vivax malaria has been perceived as a benign disease; however, it has been recently associated with a range of severe and even life--threatening manifestations.
7 In our study, 2 cases (8%) of P. vivax monoinfection fulfilled the criteria for severe malaria, and this rate was higher than 2.6% reported in an earlier multicenter European epidemiological study.
2 This result is consistent with the findings of other studies that showed a large increase in the number of severe P. vivax infections since 2000. 8 Underreporting is considered an unlikely explanation for this phenomenon, and other factors have been discussed (ie, changes in P. vivax strains virulence and geographical heterogeneity). The limitation of our study is the low number of patients, and the unusually high rate of patients with severe vivax malaria should be interpreted with caution.
Clinical and laboratory data were entered into a standardized data collection form and included into anonymous database, which was analyzed using Statistica 12 (StatSoft, Kraków, Poland). The comparison of categorical variables was performed using the Fisher exact test. Numerical variables were compared using the t test or the Mann-Whitney rank -sum test based on the distribution. A P value of less than 0.05 was considered statistically significant.
Results
The mean age of patients was 33.7 years. Vivax malaria was more often diagnosed in patients returning from South and Central America or Asia compared to Africa, where P. falciparum infections predominated (P <0.0001). Most cases of P. vivax infections (84%) were diagnosed in men. The majority of patients reported occupational travel to endemic areas (military duties and Christian missions). The mean duration of stay was 38.1 weeks. Chemoprophylaxis and personal protection measures against mosquito bites were used by a minority of patients. In 5 cases, a proper drug regimen without any missed doses was used to prevent malaria, 11 patients did not take any preventive medication, and 1 person used a proper prophylactic regimen but was not compliant. There were no data available for 8 patients.
In 5 vivax cases, the latency period was longer than 1 month. We found no significant associations between the late onset of symptoms and chemoprophylaxis use (P = 0.3), length of travel in the endemic region (P = 0.3), or history of malaria (P = 0.07).
The mean time between the onset of symptoms and diagnosis at the University Centre for Maritime and Tropical Medicine was 5 days. Fever occurred prior to hospital admission in each analyzed case. The details of reported signs and symptoms are presented in infections should be considered in patients diagnosed with imported malaria, and relapse prevention should be introduced when appropriate. The latency period, which did not seem to be affected by chemoprophylaxis use in our study, may contribute to diagnostic challenges in patients with vivax malaria with late onset of symptoms. Our findings highlight the need for considering vivax malaria as a possible cause of fever in returned travelers, irrespectively of the time from return from endemic countries and chemoprophylaxis use. This has also clear implication for pretravel medical advice with regard to destinations with P. vivax predominance, which should include the information about the possible long incubation period of tertian malaria.
